MX2019012116A - Agentes antifungicos utilizados en combinacion. - Google Patents
Agentes antifungicos utilizados en combinacion.Info
- Publication number
- MX2019012116A MX2019012116A MX2019012116A MX2019012116A MX2019012116A MX 2019012116 A MX2019012116 A MX 2019012116A MX 2019012116 A MX2019012116 A MX 2019012116A MX 2019012116 A MX2019012116 A MX 2019012116A MX 2019012116 A MX2019012116 A MX 2019012116A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- antifungal
- antifungal agents
- agents used
- relates
- Prior art date
Links
- 229940121375 antifungal agent Drugs 0.000 title abstract 5
- 239000003429 antifungal agent Substances 0.000 title abstract 3
- 230000000843 anti-fungal effect Effects 0.000 abstract 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 abstract 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 abstract 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
- 229920001503 Glucan Polymers 0.000 abstract 1
- 108010028921 Lipopeptides Proteins 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
- 229960003942 amphotericin b Drugs 0.000 abstract 1
- 150000003851 azoles Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- IAOFPTKYKOAKGZ-CRWQHXLTSA-N enfumafungin Chemical class O([C@H]1[C@H](OC(C)=O)C[C@@]23C(O)OC[C@]1(C)[C@@H]2CC[C@@H]1[C@@]2(C)CC[C@]([C@H]([C@]2(C)CC=C13)C(O)=O)(C)[C@H](C)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IAOFPTKYKOAKGZ-CRWQHXLTSA-N 0.000 abstract 1
- -1 enfumafungin derivative triterpenoids Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- DDFOUSQFMYRUQK-RCDICMHDSA-N isavuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC=C(F)C=2)F)=NC=1C1=CC=C(C#N)C=C1 DDFOUSQFMYRUQK-RCDICMHDSA-N 0.000 abstract 1
- 229960000788 isavuconazole Drugs 0.000 abstract 1
- 229960004130 itraconazole Drugs 0.000 abstract 1
- 150000004291 polyenes Chemical class 0.000 abstract 1
- 229960001589 posaconazole Drugs 0.000 abstract 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 abstract 1
- 229960004740 voriconazole Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483647P | 2017-04-10 | 2017-04-10 | |
| PCT/US2018/026088 WO2018191077A1 (en) | 2017-04-10 | 2018-04-04 | Antifungal agents used in combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019012116A true MX2019012116A (es) | 2019-11-21 |
Family
ID=62063223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012116A MX2019012116A (es) | 2017-04-10 | 2018-04-04 | Agentes antifungicos utilizados en combinacion. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11110102B2 (https=) |
| EP (1) | EP3609539A1 (https=) |
| JP (2) | JP7263313B2 (https=) |
| KR (2) | KR20240110109A (https=) |
| CN (1) | CN110769854B (https=) |
| AR (1) | AR113221A1 (https=) |
| AU (1) | AU2018253031B2 (https=) |
| CA (1) | CA3059225A1 (https=) |
| EA (1) | EA201992413A1 (https=) |
| MA (1) | MA49889A (https=) |
| MX (1) | MX2019012116A (https=) |
| TW (1) | TWI806861B (https=) |
| WO (1) | WO2018191077A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102807716B1 (ko) * | 2017-08-04 | 2025-05-13 | 싸이넥시스, 인크. | 산성 pH에서 증진된 활성을 갖는 항진균제 |
| BR112021016876A2 (pt) * | 2019-02-27 | 2021-11-03 | Scynexis Inc | Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto |
| AU2020276595B2 (en) * | 2019-05-16 | 2025-12-04 | Scynexis, Inc. | Antifungal Agents for Candida Auris Decolonization |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756472A (en) | 1996-01-31 | 1998-05-26 | Merck & Co., Inc. | Antifungal agent obtained from hormonema |
| JP5245057B2 (ja) | 2006-04-03 | 2013-07-24 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗真菌剤 |
| WO2010019204A1 (en) * | 2008-08-12 | 2010-02-18 | Merck Sharp & Dohme Corp. | Antifungal agents |
| KR101686075B1 (ko) * | 2008-08-12 | 2016-12-13 | 싸이넥시스, 인크. | 항균제 |
| CA2982660C (en) * | 2014-11-21 | 2023-01-24 | F2G Limited | 2-(1,5-dimethyl-3-phenyl-1h-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoacetamide and derivatives thereof for use as antifungal agents |
| HRP20220544T1 (hr) | 2015-01-19 | 2022-08-05 | Scynexis, Inc. | Nove soli i polimorfi scy-078 |
-
2018
- 2018-04-04 MA MA049889A patent/MA49889A/fr unknown
- 2018-04-04 US US15/945,428 patent/US11110102B2/en active Active
- 2018-04-04 CA CA3059225A patent/CA3059225A1/en active Pending
- 2018-04-04 JP JP2020504267A patent/JP7263313B2/ja active Active
- 2018-04-04 WO PCT/US2018/026088 patent/WO2018191077A1/en not_active Ceased
- 2018-04-04 AU AU2018253031A patent/AU2018253031B2/en active Active
- 2018-04-04 CN CN201880033777.4A patent/CN110769854B/zh active Active
- 2018-04-04 EP EP18720489.6A patent/EP3609539A1/en active Pending
- 2018-04-04 MX MX2019012116A patent/MX2019012116A/es unknown
- 2018-04-04 KR KR1020247022473A patent/KR20240110109A/ko active Pending
- 2018-04-04 EA EA201992413A patent/EA201992413A1/ru unknown
- 2018-04-04 KR KR1020197032870A patent/KR102683355B1/ko active Active
- 2018-04-09 AR ARP180100881A patent/AR113221A1/es not_active Application Discontinuation
- 2018-04-10 TW TW107112305A patent/TWI806861B/zh active
-
2021
- 2021-08-10 US US17/399,015 patent/US20220202833A1/en active Pending
-
2022
- 2022-12-22 JP JP2022205904A patent/JP7574268B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI806861B (zh) | 2023-07-01 |
| TW201842915A (zh) | 2018-12-16 |
| US20220202833A1 (en) | 2022-06-30 |
| KR20240110109A (ko) | 2024-07-12 |
| EA201992413A1 (ru) | 2020-03-16 |
| AU2018253031A1 (en) | 2019-10-31 |
| AR113221A1 (es) | 2020-02-19 |
| CA3059225A1 (en) | 2018-10-18 |
| JP7263313B2 (ja) | 2023-04-24 |
| KR102683355B1 (ko) | 2024-07-10 |
| JP2020513037A (ja) | 2020-04-30 |
| AU2018253031B2 (en) | 2024-04-11 |
| US11110102B2 (en) | 2021-09-07 |
| CN110769854B (zh) | 2023-01-13 |
| JP2023030113A (ja) | 2023-03-07 |
| KR20190133251A (ko) | 2019-12-02 |
| JP7574268B2 (ja) | 2024-10-28 |
| EP3609539A1 (en) | 2020-02-19 |
| CN110769854A (zh) | 2020-02-07 |
| US20180325919A1 (en) | 2018-11-15 |
| BR112019021138A2 (pt) | 2020-05-12 |
| MA49889A (fr) | 2020-06-24 |
| WO2018191077A1 (en) | 2018-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ775660A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| ECSP13013035A (es) | Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida | |
| PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| MX2021008342A (es) | Derivados de pirazol como inhibidores de calicreina plasmatica. | |
| PH12017502107A1 (en) | Triazole agonists of the apj receptor | |
| ZA201606320B (en) | Human plasma kallikrein inhibitors | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| MY194586A (en) | Anti-garp antibody | |
| UY36571A (es) | Combinaciones de compuestos activos | |
| PH12016500668A1 (en) | Active compound combinations comprising a (thio)carboxamide derivative and a fungicidal compound | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| PH12016501527B1 (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
| UY36432A (es) | Combinaciones de compuestos activos que comprenden un derivado de (tio) carboxamida y compuesto(s) fungicida(s) | |
| CO2017005990A2 (es) | Combinaciones de compuestos activos que comprenden (a) una carboxamida de indanilo difluorometil-nicotínico de fórmula (i) y otro compuesto activo como fungicida (b) | |
| UY36447A (es) | Combinaciones de compuestos activos | |
| CR20170269A (es) | Combinaciones de compuestos activos | |
| MX2019012116A (es) | Agentes antifungicos utilizados en combinacion. | |
| ZA202003281B (en) | Heterocycle substituted pyridine derivative antifungal agents | |
| MX2023001721A (es) | Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer. | |
| UY37397A (es) | Combinaciones de compuestos activos | |
| MX2020013805A (es) | Derivados de piridopirimidinona para uso como inhibidores de axl. | |
| NZ780408A (en) | Human plasma kallikrein inhibitors |